Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial

BACKGROUND: The respective benefits of high and low doses of dexamethasone (DXM) in patients with severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) and acute respiratory failure (ARF) are controversial, with two large triple-blind RCTs reaching very important difference in the effect-size....

Descripción completa

Detalles Bibliográficos
Autores principales: Chevret, Sylvie, Bouadma, Lila, Dupuis, Claire, Burdet, Charles, Timsit, Jean-François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460760/
https://www.ncbi.nlm.nih.gov/pubmed/37634234
http://dx.doi.org/10.1186/s13613-023-01168-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460760/
https://www.ncbi.nlm.nih.gov/pubmed/37634234
http://dx.doi.org/10.1186/s13613-023-01168-z

Ejemplares similares